What’s Propelling Puma Biotechnology Inc (NASDAQ:PBYI) After Lower Shorts Reported?

August 9, 2018 - By Vernon Prom

Investors sentiment decreased to 1.14 in 2018 Q1. Its down 0.51, from 1.65 in 2017Q4. It worsened, as 35 investors sold Puma Biotechnology, Inc. shares while 44 reduced holdings. 21 funds opened positions while 69 raised stakes. 34.13 million shares or 1.66% less from 34.70 million shares in 2017Q4 were reported.
Qs Investors Limited Com has invested 0% in Puma Biotechnology, Inc. (NASDAQ:PBYI). Pictet Asset Mngmt Limited holds 288,480 shares. 20,808 are owned by Ubs Asset Management Americas. Clear Harbor Asset Mgmt Limited Liability Corp has 3,360 shares for 0.04% of their portfolio. Envestnet Asset Management accumulated 0% or 198 shares. Proxima Cap Mgmt Ltd owns 30,000 shares or 1.12% of their US portfolio. Vanguard Group Inc reported 2.65M shares. 39,107 were reported by Jpmorgan Chase &. Venbio Select Advisor Limited Liability invested in 825,368 shares. 55,985 were reported by Tekla Capital Mngmt Limited Liability Company. Adage Cap Gp Limited Liability Company holds 322,000 shares. Jennison Associates stated it has 485,545 shares. Sg Americas Ltd Liability Corporation has invested 0% in Puma Biotechnology, Inc. (NASDAQ:PBYI). Dupont Capital Mngmt Corp holds 34,613 shares or 0.06% of its portfolio. Rock Springs Capital Mngmt Ltd Partnership invested 1.2% of its portfolio in Puma Biotechnology, Inc. (NASDAQ:PBYI).

Since June 1, 2018, it had 0 buys, and 5 insider sales for $937,634 activity. On Friday, July 20 AUERBACH ALAN H sold $651,020 worth of Puma Biotechnology, Inc. (NASDAQ:PBYI) or 12,520 shares. EYLER CHARLES R sold $31,690 worth of Puma Biotechnology, Inc. (NASDAQ:PBYI) on Friday, July 20. Lo Steven also sold $95,360 worth of Puma Biotechnology, Inc. (NASDAQ:PBYI) on Friday, July 20.

The stock of Puma Biotechnology Inc (NASDAQ:PBYI) registered a decrease of 0.41% in short interest. PBYI’s total short interest was 3.10M shares in August as published by FINRA. Its down 0.41% from 3.11M shares, reported previously. With 486,000 shares average volume, it will take short sellers 6 days to cover their PBYI’s short positions. The short interest to Puma Biotechnology Inc’s float is 11.25%.

The stock increased 1.55% or $0.75 during the last trading session, reaching $49.05. About 214,157 shares traded. Puma Biotechnology, Inc. (NASDAQ:PBYI) has declined 33.50% since August 9, 2017 and is downtrending. It has underperformed by 46.07% the S&P500.

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to improve cancer care. The company has market cap of $1.86 billion. The Company’s drug candidates include PB272 ) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 (neratinib (intravenous)). It currently has negative earnings. The firm also develops PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4.

More notable recent Puma Biotechnology, Inc. (NASDAQ:PBYI) news were published by: Businesswire.com which released: “Puma Biotechnology Files New Drug Submission for NERLYNX® in Canada” on July 31, 2018, also Fool.com with their article: “Here’s Why Puma Biotechnology Rose 11.7% in June” published on July 13, 2018, Benzinga.com published: “Earnings Scheduled For August 9, 2018” on August 09, 2018. More interesting news about Puma Biotechnology, Inc. (NASDAQ:PBYI) were released by: Businesswire.com and their article: “Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results” published on July 26, 2018 as well as Benzinga.com‘s news article titled: “The Daily Biotech Pulse: FDA Panel Backs Insmed, Eidos’ Maiden Earnings, Paratek Awaits Adcom Verdict” with publication date: August 08, 2018.

Puma Biotechnology, Inc. (NASDAQ:PBYI) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.